The detailed mode of action of the CD30 antibody-drug conjugate BV in DLBCL is not well understood in all aspects since the clinical outcome seems to be partially independent of the CD30 expression on the tumor cells. The gene discussed is TNFRSF8; the disease is diffuse large B-cell lymphoma.